Who are RSVpreF 120 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): recombinant subunit Herpes zoster vaccine, Zoster Vaccine Recombinant, Zoster Vaccine Recombinant, Adjuvanted, recombinant adjuvanted zoster vaccine, RZV, HZ/su.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rsvpref-120-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

RSVpreF 120 µg — Competitive Intelligence Brief

RSVpreF 120 µg (rsvpref-120-g) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant subunit vaccine. Area: Immunology.

marketed Recombinant subunit vaccine Prefusion form of the RSV F protein Immunology Live · refreshed every 30 min

Target snapshot

RSVpreF 120 µg (rsvpref-120-g) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RSVpreF 120 µg TARGET	rsvpref-120-g	Pfizer	marketed	Recombinant subunit vaccine	Prefusion form of the RSV F protein
recombinant subunit Herpes zoster vaccine	recombinant subunit Herpes zoster vaccine	University Health Network, Toronto	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant	Zoster Vaccine Recombinant	University of Colorado, Denver	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant, Adjuvanted	Zoster Vaccine Recombinant, Adjuvanted	Wuhan BravoVax Co., Ltd.	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
recombinant adjuvanted zoster vaccine	recombinant adjuvanted zoster vaccine	Wuerzburg University Hospital	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
RZV	RZV	GlaxoSmithKline	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
HZ/su	HZ/su	GlaxoSmithKline	phase 3	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant subunit vaccine class)

GlaxoSmithKline · 3 drugs in this class
Pfizer · 1 drug in this class
Sinovac (Dalian) Vaccine Technology Co., Ltd. · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RSVpreF 120 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/rsvpref-120-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab